At 28 h post-injection (hpi), we observed that the relative growth of the tumor within the yolk sac was much lower after injection of shANXA2 MDA-MB-231 cells as compared to control cells, suggesting reduced survival of ANXA2-deficient cells (Fig. 6B). This evidence concerns the gene ANXA2 and neoplasm.